肉瘤新药他泽司他获批上市！

Sarcomas are extremely rare tumors. Epithelioid sarcoma is a very rare and extremely aggressive soft tissue sarcoma for which there is currently no particularly effective treatment. On January 24, 2020, it was approved by the US FDA for the treatment of adults and pediatric patients 16 years and older with metastatic/locally advanced epithelioid sarcoma (ES) who are not suitable for complete resection. Tazerestat became the first and only approved EZH2 inhibitor.

Tazetostat can benefit more patients with advanced sarcoma. A single-arm multicenter study (EZH-202 study cohort 5, NCT02601950) enrolled histologically confirmed, metastatic or locally advanced epithelioid sarcoma. Enrolled patients are required to use local testing to confirm that they carry the INI1 gene deletion and have an ECOG PS score of 0-2. Patients received tazerestat 800 mg orally twice daily until disease progression or intolerable toxicity. Cohort 5 enrolled 62 patients, and the ORR was 15%. Among them, 1.6% of patients achieved complete response, and 13% of patients achieved partial response. Among the patients who achieved curative effect, 67% of the patients had a curative effect that lasted for 6 months or more.

In terms of safety, pain, fatigue, nausea, decreased appetite, vomiting, and constipation are common side effects of tazerestat in the treatment of patients with epithelioid sarcoma. Patients' constitutions and conditions are different, and side effects are also different. Tazerestat is an oral medication. The recommended dose is 800 mg twice daily. It can be taken with or without food. However, patients are advised not to change the dosage and usage at will, so as not to affect the original condition. Patients should also be treated symptomatically and not blindly take medication.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: